Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from

and

Download Data

Freeline Therapeutics Holdings Plc Property, Plant, Equipment (Net) 3 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023: 22.94%

Freeline Therapeutics Holdings Plc Property, Plant, Equipment (Net) 3 year CAGR is 22.94% for the Trailing 12 Months (TTM) ending September 30, 2023. Property, Plant, Equipment (Net) is the net value of a company's tangible assets, such as buildings, machinery, and equipment, after deducting accumulated depreciation. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Freeline Therapeutics Holdings Plc Property, Plant, Equipment (Net) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 22.49 M, a 121.76% change year over year.
Freeline Therapeutics Holdings Plc Property, Plant, Equipment (Net) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 10.14 M.

NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO	Mr. Michael J. Parini J.D.
IPO Date	Aug. 7, 2020
Location	United Kingdom
Headquarters	Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key trends